Search clinical trials for: ORE1001

Total 29 results

Ore Pharmaceuticals, Inc.

Unknown

Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis

Mild to Moderate Ulcerative Colitis

Canada, India
ObsEva SA

Completed

OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI (IMPLANT)

Infertility

Poland, United Kingdom, Spain, Belgium, Denmark, Czechia
Orinove, Inc.
Fosun Pharma

Active, not recruiting

Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.

Effect of Drug

China
Reneo Pharma Ltd

Completed

A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders

Fatty Acid Oxidation Disorders

United States, France, Spain
Orinove, Inc.
Vanderbilt University

Active, not recruiting

Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States
Reneo Pharma Ltd

Terminated

An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

Primary Mitochondrial Myopathy

Spain, Australia, Belgium, Denmark, Canada, United Kingdom, France, Germany, Hungary, Italy, Netherlands, New Zealand
Reneo Pharma Ltd

Completed

A Study of the Safety of REN001 in Patients With McArdle Disease

McArdle Disease

Spain, United Kingdom
Reneo Pharma Ltd

Terminated

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

Primary Mitochondrial Myopathy

United Kingdom
AriBio Co., Ltd.

Recruiting

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

Alzheimer Disease

United States, Korea, Republic of
AriBio Co., Ltd.

Completed

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

Mild to Moderate Alzheimer's Disease

United States
ObsEva SA

Terminated

A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth (TERM)

Preterm Labor

Poland, United Kingdom, Spain, Switzerland, Belgium, Germany
Renovo

Completed

Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects

Cicatrix

United Kingdom
Reneo Pharma Ltd

Completed

An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients (STRIDE)

Primary Mitochondrial Myopathy

United States, Spain, Australia, France, United Kingdom, New Zealand, Denmark, Norway, Czechia, Belgium, Canada, Germany, Hungary, Italy, Netherlands
Renovo

Completed

Juvista in Scar Revision Surgery of Disfiguring Scars (Revise)

Cicatrix

Spain, France, Hungary, Italy, United Kingdom, United States, Denmark, Germany, Latvia, Poland
University of Calgary
3M

Completed

Negative Pressure Dressing After Saphenous Vein Harvest

Coronary Artery Disease | Wound Complication | Complication of Coronary Artery Bypass Graft

Canada
Origin Biosciences

Completed

Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP

Molybdenum Cofactor Deficiency, Type A

United States, Australia, Netherlands, United Kingdom, Tunisia
Origin Biosciences

Completed

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

Molybdenum Cofactor Deficiency, Type A

United States, Spain, Israel, Norway, Turkey, United Kingdom
Renovo

Completed

Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites

Cicatrix | Wound Healing

United Kingdom
Renovo

Completed

Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)

Cicatrix | Wound Healing

United Kingdom
Renovo

Completed

Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)

Cicatrix | Wound Healing | Re-epithelialization

United Kingdom
Renovo

Completed

A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo (RN1006)

Scar Improvement

United Kingdom
Orinove, Inc.

Active, not recruiting

ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

Metastatic Breast Cancer | Advanced Solid Tumor

United States
Renovo

Completed

Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects

Cicatrix | Wound Healing

United Kingdom
Renovo

Completed

Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males

Cicatrix

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris (OREA)

Acne Vulgaris | Acne

Germany
Renovo

Completed

Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women

Cicatrix

United Kingdom
Renovo

Completed

Scar-Improvement Efficacy and Safety of a Single Intradermal Injection of Avotermin (Juvista) Administered Following Full-Thickness Skin Incisions

Cicatrix

United Kingdom
Orexa BV
QPS Holdings LLC

Recruiting

Preventing Gastrointestinal Disturbance in Patients After Longitudinal Laparotomy. (ORE001PIIPOI)

Ileus Postoperative

Germany
Maastricht University Medical Center
University of Bern; University of Freiburg

Unknown

Electromechanical Profiling of the Long-QT Syndrome (LQTS) (EMLoQ)

Ventricular Tachycardia | Sudden Cardiac Death | Long QT Syndrome

3

Subscribe